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Highlights: 
• Transferrin injection in the eye has no deleterious effect on retinal structure 
• Local delivery of transferrin protects photoreceptors and preserves retinal electrophysiological 
activities in light-induced retinal degeneration model 
• Protective mechanisms of tranferrin result from control of iron-induced death decrease and 
modulation of inflammation 
• Intraocular administration of transferrin has  therapeutic potential in retinal degenerative 
diseases 
Graphical abstract: 
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ABSTRACT  
Iron is essential for retinal function but contributes to oxidative stress-mediated degeneration. Iron 
retinal homeostasis is highly regulated and transferrin (Tf), a potent iron chelator, is endogenously 
secreted by retinal cells. In this study, therapeutic potential of a local Tf delivery was evaluated in 
animal models of retinal degeneration.  
After intravitreal injection, Tf spread rapidly within the retina and accumulated in photoreceptors 
and retinal pigment epithelium, before reaching the blood circulation. Tf injected in the vitreous prior 
and, to a lesser extent, after light-induced retinal degeneration, efficiently protected the retina 
histology and function. We found an association between Tf treatment and the modulation of iron 
homeostasis resulting in a decrease of iron content and oxidative stress marker. The 
immunomodulation function of Tf could be seen through a reduction in macrophage/microglial 
activation as well as modulated inflammation responses. In a mouse model of hemochromatosis, Tf 
had the capacity to clear abnormal iron accumulation from retinas. And in the slow P23H rat model of 
retinal degeneration, a sustained release of Tf in the vitreous via non-viral gene therapy efficently 
slowed-down the photoreceptors death and preserved their function.  
These results clearly demonstrate the synergistic neuroprotective roles of Tf against retinal 
degeneration and allow identify Tf as an innovative and not toxic therapy for retinal diseases 
associated with oxidative stress. 
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INTRODUCTION 
Oxidative stress and inflammation are recognized as major pathological processes in 
neurodegenerative diseases and iron is identified as a catalyzer of both processes (1-3). In the retina, 
iron is essential for photoreceptors (PR) activity as it is a cofactor of phototransduction enzymes (4-5). 
Iron content within the retina is generally controlled through locally expressed iron-related proteins (6-
7). Nevetheless, iron excess can be found in the retina of elderly people (8) and is known to 
accumulate in retinal diseases (2, 9). For instance, in age-related macular degeneration (AMD), the 
common leading cause of blindness in industrialized countries, iron deposits can be found in PR 
segments, retinal pigment epithelium (RPE) and in drusen (sub-RPE deposits characteristic of AMD) 
(10). Moreover, increased iron concentration level are usually detected in the aqueous humor AMD 
patients (11). Free iron is shown to be highly toxic for PR (12), which loss lead to irreversible damage 
and thus to blindness. Similarly, we showed that iron accumulation and alteration of iron metabolism 
are both correlated with the progression of PR degeneration in animal models of retinal degeneration 
(rd10 mice and Royal College of Surgeons (RCS) rats) (13-15). Therefore, iron chelation allowing the 
removal of excess iron may very likely be a therapeutic target (16-17). Indeed, the use of chemical 
iron chelators such as deferoxamine and deferiprone administered by systemic or oral routes, were 
reported to be efficient in preventing PR death in animal models of retinal degeneration (14, 18-21). 
Nevertheless, the long-term systemic delivery of iron chelator may cause refractory iron depletion and 
may not be the best treatment option especially in elderly patients frequently suffering from anemia 
(22-23).  
Our previous investigations showed that human transferrin (Tf), whether continuously expressed or 
administered intraperitoneally, preserve more than 60% of PR from death in rd10 mice (24-25). 
Indeed, Tf, the main iron transporter, is a natural iron chelator essential for homeostasis control (24, 
26). Our study is the first attempt to directly injected an iron chelator into the eye. We performed 
intravitreal injections of human Tf in two different rat models of retinal degeneration and subsequently 
analyzed the pathways involved in its protective effect. We first used a light-induced retinal 
degeneration model in which oxidative stress is prominent (27-28). This allowed us to screen the 
optimal doses, the administration routes of Tf and its toxicity threshold. We simultaneously evaluated 
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the effects of Tf on iron metabolism, apoptosis and inflammation responses. In a second step, we used 
P23H rats suffering from slow retinal degeneration and used a non-viral gene therapy to evaluate 
whether sustained intra-ocular Tf production could delay the inherited degeneration.  
This study highlights the therapeutic potentiel of local delivery of Tf on neuronal loss, oxidative stress 
and inflammation, the pathological features commonly observed in neurodegenerative diseases.  
 
RESULTS  
Time-related distribution of transferrin after intravitreal injection 
We used Tf labeled with fluorochrom Alexa 488 (Tf-Alexa) to follow the fate of Tf in the rat retina 
after intravitreal (IVT) injection. Two hours after injection, Tf-Alexa could be detected throughout the 
retina, and was localized in retinal capillaries (arrowhead) and in the retinal pigment epithelium (RPE) 
(Figure 1A, left panel). A combination of Müller glial cells marker (Figure 1A, middle panel)  with Tf-
Alexa allowed us to show that Tf-Alexa was present along those cells, with largest concentrations in 
their end feet facing the vitreous (Figure 1A, right panel). Confocal microscopy conferring higher 
resolution allowed us to localize Tf-Alexa in microvillosities of RPE (Figure 1B) and in the inner and 
outer segments of rod PR (Figure 1C). Tf receptor 1 and TfR2 were widely expressed in the retina (26, 
29). Tf-Alexa was co-localized with TfR1 in the inner plexiform layer (IPL), outer plexiform layer 
(OPL), inner segments (IS) and RPE (Figure 1D), and with TfR2 in IPL, ONL and IS (Figure 1E). Six 
hours after injection, Tf-Alexa had the same pattern, and was additionally detected within  
choriocapillaries  (Figure 1F).  
We used a specific transferrin (Tf)-ELISA assay to quantify Tf levels in ocular fluids and tissues after 
IVT injection of human Tf in rat eyes. ELISA assays were performed at 6, 24 hours and 7 days after 
injection (Figure 1G-H). When comparing Tf content 6 and 24 hours after injection, we observed a 
significant decrease of 67.3% in the neural retina and of 82.6% in the eye cup (Figure 1G). In ocular 
fluids, Tf concentration was higher in aqueous humor than in the vitreous, and increased with time 
(Figure 1H). Tf levels measured in the systemic circulation were of 56.6 ng/ml ±0.32 and 46.5 ng/ml 
±5.77, 6 and 24 hours after injection. Finally, Tf was undetectable in both, eyes and plasma 7 days 
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after injection. These data indicate that IVT injected Tf reach the retina in a short amount of time and 
most likely via the Tf receptor 1. It subsequently accumulate in RPE cells and finally disappear 
through choroidal blood circulation. 
 
Transferrin intravitreal injection has no deleterious effect on normal retina 
We injected Tf in vitreous of rats and analyzed the retina and its histology 7 days later. Some rats 
obtained a single injection and others received a second injection 7 days after the first one. In vivo 
optical coherence tomography (OCT)  imaging revealed no retinal structure modifications after one or 
two injections (Figure 2A). We used OCT pictures to measure ONL thickness which is usually 
correlated to PR nuclei number, and observed no differences among control not injected rats, and 
animals injected once or twice with Tf (Figure 2B). Moreover, when compared to eyes from control 
rats, rat eyes injected twice with Tf showed no substantial histological modifications in any layer 
(Figure 2C). Finally, an analysis of ONL thickness on sections crossing the optic nerve showed no 
significant difference between control and treated rats (Figure 2D) and thus confirm results obtained 
from OCT recording.  
 
Transferrin intravitreal injection protects photoreceptors nuclear layer 
Light-induced damage is a commonly used model to evaluate neuroprotective drugs on PR 
degeneration (28, 30-31). We injected Tf in the vitreous directly after a dark adaptation period of  18 
hours. We further exposed the rats to intense light during 24 hours. We performed morphological 
analysis 8 days after light exposure using OCT recordings as well as histological semi-fine sections. 
OCT images realized at superior pole of rats injected with control solution (BLE group) showed a 
reduction in ONL thickness. Tf treatment (TfLE group) seemed to preserve the retina against light 
effects (Figure 3A). The ONL thickness measured on OCT images (Figure 3B) showed a significant 
decrease of 56% in BLE rats as compared to rats neither injected nor exposed to light (NLE group). 
There was no significant difference in ONL between TfLE rats and NLE rats. Histology confirmed 
OCT observations and measurements (Figure 3C-D). The most severe light-induced damage of BLE 
retinas was been observed occurring close to the optic nerve and especially on the superior side. The 
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rats treated with Tf had a preservation of ONL, IS, OS and RPE as compared to BLE rats (Figure 3C). 
ONL thickness measured throughout the retina showed that 70% of the PR nuclei at the superior pole 
and 92% at the inferior pole were protected with Tf injection (Figure 3D).  
 
Transferrin preserves PR structures and functions. 
We assessed apoptotic cells by TUNEL staining on eye cryosections to better evaluate the preservation 
of PR nuclear layer with Tf treatment (Figure 4A). One day after light exposure, many TUNEL 
positive PR were present in the ONL of BLE rats. TUNEL intensity staining quantification in ONL 
throughout the retina demonstrated a significant reduction of 40% in the number of apoptotic PR in 
TfLE retinas as compared to BLE (Figure 4B). We stained rods by rhodopsin immunodetection and 
cone by lectin-peanut labeling 8 days after light exposure to confirm Tf-treatment PR morphological 
preservation. When compare to unexposed eyes (NLE), BLE retinas had a close to complete loss of 
both types of PR (Figure 4C, middle panel), whereas Tf-treatment retinas (TfLE) showed preserved 
structures in both rods and cones (arrows) (Figure 4C, right panel).  
We performed full-field electroretinograms 16 days after light-exposure to determine whether the 
above-described results correlate with the maintenance of retinal function. In scotopic conditions, 
light-exposure drastically lowered a- and b-wave amplitudes in BLE rats, meaning a decreased rod-
driven response (Figure 4D). With Tf treatment, these amplitudes were significantly higher compared 
to BLE group (Figure 4D). In an extensive analysis in the flash intensity ranging from -0.5 to 0.47 
log(cd.s/m2), the mean a-wave amplitude of TfLE reached 55.18% of NLE, and the mean b-wave 
amplitudes in TfLE rats were 47% of NLE values. The protection of scotopic a- and b-wave 
amplitudes were confirmed by the mixed rod-cone responses recording (Supp. Figure 1). Tf 
significantly preserved 85% of PR response (a-wave amplitude; Supp. Figure 1A left panel), and 
54.8% of internal retina response (b-wave amplitude;  Supp. Figure 1A right panel) relative to 
unexposed rats. The time-to-peak for mixed ERG a- and b-waves were not statistically different in the 
three rat groups, in spite of a tendency toward a Tf-induced preservation of implicit times (Supp. Fig 
1B). Following a rod-suppressing light adaptation, the photopic b-wave responses (Figure 3E, left 
panel), specific for cone responses were recorded. Nonetheless, the amplitudes did not differ between 
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BLE and TfLE. These were lower compared to NLE. The implicit time (right panel) was significantly 
longer in BLE as compared to NLE, and significantly restored in TfLE rats. To better characterize this 
effect on cones, we quantified cones in overall retina (Figure 4F). Eight days after light exposure, there 
was a 43% cone loss in BLE retinas and a 23% cone loss in TfLE retinas when expressed as % of 
cones within the control NLE group. In conclusion, IVT injection of Tf was effective in protecting 
cones and rods from death and allowed to preserve the physiological activities of the retina against 
light-induced retinal damages. 
 
Iron metabolism deregulation in light-damage retina is restored by transferrin IVT injection  
Previously publications showed that intense light-exposure induces an acute and rapid modification of 
iron metabolism that persists for several days after light damage (25, 32). To evaluate the effects of Tf 
in iron homeostasis, we investigated the regulation of iron-related genes and proteins as well as the 
iron content and distribution after light-exposure. 
One day after light exposure, quantitative RT-PCR (Figure 5A) on neural retinas monitored expression 
of genes related to iron transport (Tf and TfR1), storage (heavy and light Ferritins (FtH and FtL)), 
export (Divalent metal transporter 1 (Dmt1), Ferroportin (Fpn) and Ceruloplasmin (Cp)), and 
regulation (TfR2, Human hemochromatosis protein (Hfe) and Hemojuvelin (Hjv)). Except for Cp and 
FtL, transcripts of all analyzed iron-related genes significantly decreased in BLE rats as compared to 
control NLE rats. In Tf treated retinas, the expression of Tf, TfR1, Dmt1, Hfe and Hjv mRNA was 
partially but significantly restored as compared to BLE retinas. The light-induced expression of Cp 
was significantly increased in TfLE rat retinas. Tf treatment had no significant effect on FtH, FtL, Fpn 
and TfR2 transcription when compared to BSS injected rat retinas. 
Using immunohistochemistry, we observed the expression of the two ferritins and TfR1 proteins at 
differents time points after the light-exposure (Figure 5B-D). The expression of these proteins are 
known to correlated with the retina iron content, regulated by iron regulatory proteins IRP1 and IRP2 
(25, 33). One day after light exposure, no modification of the two ferritins staining was observed in 
BLE and TfLE treated groups as compared to NLE (data not shown). At day 3 and 8, ferritin staining 
intensity was increased in the retina of BLE rats (Figure 5B-C, central column) whereas no obvious 
 10
modification was observed in the retina of TfLE rats when compared to NLE rats (right compared to 
left column). While TfR1 decreased in the retinas of BLE rat (Figure 5D, central panel), it remained 
similar to the retinas of NLE rats in the TfLE rat eyes (right panel). Given the previous results, we 
explored whether Tf treatment had an impact on iron accumulation in the retina, and revealed non-
heminic iron using Perls Prussian blue reaction intensified with diaminobenzidine (Figure 5E). Iron 
accumulated  in the outer retina of BLE rat at day 3 and 8 after light exposure (Figure 5E, middle 
panel). Such an accumulation could not be detected in the retinas of TfLE rat at any time point (Figure 
5E, right panel). This was confirmed with the total non-heme iron quantification determined in neural 
retinas at 8 days after light exposure (Figure 5F) and demonstrates that Tf significantly prevent free 
iron content increase. To investigate the effect of Tf on oxidative stress, we assessed heme oxygenase 
(Hmox1) mRNA expression using qPCR on neural retina one day after light-exposure. Light-induced 
iron overload significantly increases Hmox1 in the BLE group. This upregulation was less important in 
the retinas of rats treated with Tf  (Figure 6). These results demonstrated that IVT of Tf allows a rapid 
and efficient control of iron homeostasis thereby avoiding iron accumulation and oxidative stress.  
 
Light-induced retinal inflammation is controlled by transferrin. 
Microglial cells (MC), specific macrophage/monocyte of the retina, are activated by light exposure 
and migrate towards PR debris (34-35). We used ionized calcium-binding adapter molecule (Iba1) and 
CD68 as markers to reveal macrophage/monocyte. Both are constitutively expressed but CD68 is 
restricted to lysosomal membranes of non-activated cells, and is expressed in the cytoplasm of 
activated cells, allowing the discrimination of the activation state at 1, 3 or 8 days after light-induced 
damage (Figure 7A-H). We localized non-activated MC in the inner retina of NLE rats (arrow, Figure 
7A). Twenty-four hours after light-damage, Iba1 positive cells had migrated towards the outer retina in 
both rats and most of them were CD68- (arrows, Figure 7B-C). At 3 days, numerous round Iba1+ cells 
increased in outer retina in BLE and TfLE rats (Figure 7D-E). Higher magnification of subretinal 
space revealed that the Iba1+ cells were CD68+ in BLE rats, while Iba1+/CD68- cells reprensented the 
majority in TfLE rats (Figure 7D2-E2). CD68+/Iba1+ intensity ratio quantifed in cells staining in the 
outer retina (Figure 7F) show that the majority of Iba1+ cells were also CD68+ in BLE rats. This was 
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true only for half the cells within the TfLE group. At 8 days (Figure 7G-H), numerous Iba1+/CD68+ 
amoeboid cells remained in the outer part of retina of BLE rats (arrows), while Iba1+ non-activated 
cells were localized in the inner retina in the TfLE group (arrowheads). 
To get a better picture of the effect of Tf on light-induced retinal inflammation, we performed a PCR 
array on 84 genes of inflammatory mediators on the neural retina, 1 day after light exposure. In the 
BLE group, 34 genes were up-regulated  and 13 down-regulated when compared to the NLE control 
group. When comparing the TfLE group to the NLE group, 42 genes were up-regulated and 9 down-
regulated (Table 1). Figure 8 shows gene distribution differentially regulated in TfLE when compared 
to BLE according to theirs p-value versus fold change. Ccl5, Ccl6, Cxcl3, Cxcl5, Il9 genes were 
significantly upregulated, whereas Il23r, Il22, Il1rap and Faslg were down-regulated. List of genes 
modified by one-third by Tf injection are indicated in Supplemental Table 2. All these data indicate 
that IVT of Tf control inflammatory cell activities through the modulation of inflammatory mediators 
induced during light-exposure. 
 
Transferrin has a long-term effect and efficacy in advanced disease models.  
To evaluate the effectiveness of Tf in animals models presenting pathogenic characteristics such as 
iron accumulation, photoreceptors degeneration and long-term disease evolution: 1- we administered 
Tf treatment when part of the retina had already been damaged through light exposure; 2- we induced 
sustained expression of Tf, via ciliary muscle electroporation of a plasmid encoding human Tf, in the 
P23H rat model of slow retinal degeneration; 3- we tested the efficacy of Tf in removing iron deposits 
from the retina of the Bmp6-/- mouse genetic model presenting iron overload.  
1- Effect of IVT Tf treatment on partially degenerated retina. In retinal disease, PR death begins 
before diagnosis, and therefore prospective treatments would have to be initiated in deleterious 
conditions. The onset of light-induced retinal damage is rapid, occurring in about 2 hours after light 
exposure. Once started PR degradation continues for a 2 days period (36). To demonstrate that Tf can 
protect PR even after the degenerative process has begun, we performed IVT injection subsequent to 
light-exposure. Eight days after the injection, ONL was mainly destroyed in BLE rats (Figure 9A, 
arrows). Throughout the entire BLE rat retina, the mean ONL thickness was 12.5% of the NLE (NLE: 
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39.43µm ±1.10; BLE: 5.94µm ±0.40) (Figure 9B). In the TfLE group, Tf was not able to protect the 
PR layer at the superior pole, which was largely destroyed. However, relative to NLE rats, 50% of PR 
nuclei were preserved in the inferior pole (mean ONL thickness of NLE: 40.43µm ±1.51; TfLE: 
20.3µm ±2.72). This suggests that Tf injection may have a protective effect on partially damaged 
retinas. 
2- Sustained production of Tf by gene therapy in slow retinal degeneration model. IVT injections are 
routinely used for eye treatment. In the context of chronic diseases such as dry AMD, frequent 
intraocular injections may contribute to reduce treatment compliance. Our laboratory has developed a 
non-viral gene therapy strategy based on ciliary muscle cells transduction via electrotransfer (ET) 
thereby serving as a biofactory for sustained production of therapeutic proteins in the vitreous 
(37). Using a disposable device and a minimally invasive procedure, this gene therapy technique can 
be applied to secrete proteins of any molecular weight for several months (38-39). We produced 
pVAX1-Tf plasmid through subcloning the cDNA of human Tf in a pVAX1 backbone under a 
cytomegalovirus-β promoter which is known to be efficient for ET protocol (38). We transfected 
human immortalized RPE cell line (ARPE-19) that does not synthesize Tf with pVAX1-Tf and 
immunoblotted the culture media. The size of the produced Tf was similar to Tf isolated from human 
plasma (Supp. Figure 2A). We used Tf-ELISA assay to determine the amount of Tf produced in the rat 
eye 3 days after after ET. We detected human Tf in all compartments of the eye, including the 
vitreous, aqueous humor and neural retina as well as the eye cup (Supp. Figure 2B). When performing 
retinal histology 12 days after ET, we did not observe any difference in eyes ET with empty pVAX1 
as compared to control eyes and did not see any variation of ONL thickness for eyes in which we 
induced Tf production (control: 45.11µm ±1.82; ET pVAX1: 45.97µm ±1.92; ET pVAX1-Tf: 
43.03µm ±1.31) (Figure 10A-B). We performed ET 3 days before exposing rats to light to evaluate in 
oculo the efficacy of produced Tf on PR degeneration (Figure 10C-D). ET of empty pVAX1 plasmid 
did not have a significant impact on light-induced retinal damage (mean of ONL thickness of rat 
exposed to light (LE): 18.78µm ±0.69 compared to rat injected with pVAX1 and exposed to light: 
15.71µm ±0.89), whereas plasmid induced-Tf allowed to preserve 67% of ONL thickness as compared 
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to rats not exposed (rat injected with pVAX1-Tf and exposed to light: 30.10µm ±2.08 versus control 
not light-exposed figure 10B).  
We further  tested the efficiency of Tf production in the P23H rhodopsin transgenic rat model of 
gradual PR loss, a model of autosomal dominant retinitis pigmentosa (40). We induced ET with 
pVAX1-Tf or empty-plasmid when PR loss had already begun (4 weeks-old rats) and collected the 
eyes 4 weeks later. Eight week-old P23H control rats presented nearly one fourth of ONL thickness as 
compared to control wild-type rats (Figure 10E-F compare to 10A-B) (P23H: 12.83µm ±0.72). 
Synthesis of Tf in P23H eye significantly preserved PR nuclei as compared to P23H eyes 
electrotransfered with empty pVAX1 (P23H rats ET with pVAX1: 10.61µm ±1.17; P23H rats ET with 
pVAX1-Tf: 16.15µm ±0.71) (Figure 10 E-F). These results demonstrate that Tf expressed in the eye 
via gene therapy can protect the retina from retinal degeneration whether acute or progressive.  
3- Iron removal in a mouse model of iron retinal overload. In AMD, iron accumulates in RPE, drusen 
and outer segments of PR (8). We used mice knock-out for the Bone Morphogenetic Protein 6 (Bmp6) 
gene, a model of hemochromatosis to validate the effect of Tf in reducing iron deposits in the retina. 
By binding with its specific receptor, BMP6 protein activates transcription of the hepcidin gene. This 
peptidic hormone blocks iron cellular exportation by activating ferroportin proteolysis. In Bmp6 KO 
mice eyes, we detected iron deposits in the RPE at 22 weeks and also in inner segments of PR in older 
mice (data not shown). Bmp6 KO mice develop severe retinal degeneration by 41 weeks (41). We used 
32 week-old mice already presenting iron overload in the RPE to test the efficacy of iron-removal by 
Tf (Figure 11A-B). We used two different protocols of Tf adminstration: 3 intraperitoneal injections 
per weeks over a one-month period, or a single IVT injection 7 days before eyes collection. As 
observed in Figure 11A, iron deposits on the basolateral side of RPE were partially removed with 
systemic infusion. Both treatment protocols significantly reduced iron deposits in the RPE by nearly 
10% (IP BSS: 102.1 ±2.6; IP Tf: 91.47±2.35; IVT BSS: 105.5 ±3; IVT Tf: 97.71 ±3.74) (Figure11B). 
Tf was efficient to remove iron accumulation. 
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DISCUSSION  
In the present study, we investigated whether intravitreal injection of the endogenous iron chelator, 
transferrin, is efficient to prevent and protect PR against degeneration in several animal models.  
The pathogenic role of iron is recognized in neurogenerative retinal diseases and the use of iron 
chelators (deferoxamine, deferiprone or deferasirox) has been already evaluated (42-45). Oral 
deferiprone has been the most studied drug in different murine models of retinal degeneration 
(hereditary, light- or iron-induced) and had a protective effect on PR (19-20, 46-47). However, in the 
absence of iron overload, systemic iron chelation therapy raises safety issues including chelator 
overdose toxicity, iron and other essential metal deficiencies as well as diseases associated with such 
metabolic imbalance. Ocular toxicity including cataract, maculopathy, and optic neuritis has been 
reported in patients treated with deferoxamine or deferasirox during an extended period (48-50).   
Aside from the synthetic (as deferiprone or deferasirox) and phytochemical chelators (curcumin, R-
lipoic acid), Tf is an endogenous and potent iron chelator locally produced by ocular cells. Its main 
property is to control iron content in order to avoid any free labile iron, known to be a source of 
oxidative stress and cell death. Systemic administration of Tf exerted strong neuroprotective effects on 
rodent models of retinal dystrophies (14), positioning Tf supplementation as a therapeutic option for 
patients with retinal degeneration. For clinical use, parenteral administration is not adapted, 
particularly if long-term treatment is envisaged. We therefore conducted this extensive study to 
explore and better understand the effects of Tf administered locally through an intravitreous route. 
When injected into the vitreous, Tf rapidly penetrated into the retina through Müller glial cell end feet 
at the vitreous border. The presence of Tf in choroidal capillaries within a few hours after its 
intravitreal injection suggests that Tf follows a transretinal elimination route through Tf-receptors 
localized on vascular endothelial cell. Indeed, we detected Tf in plasma already 6 hours and up to 7 
days after IVT injections, demonstrating a quick turn-over of Tf in the retina. This led us to inject Tf 
just before or just after a 24 hours continuous light exposure.  
In  acute models of light-induced retinal degeneration, PR death occurred within one day and was 
associated to retinal inflammation and iron homeostasis remodeling (14, 32, 35). The local 
administration of Tf before light exposure, allowed morphological preservation of 70% of PR cells 
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(Figure 3C, 4C). Electroretinograms recording allowed us to confirmed the functionality of PR cells 
with 50% of rod-driven electrical responses and an improved cone response time, indicating 
preservation of cone and rod responses and synaptic connections with retinal neurons (Figure 4D-F). 
These protective effects of IVT of Tf were associated with a decrease in apoptotic cells (Figure 4A) 
and a reduction of oxidative stress-induced heme oxygenase expression (Figure 6).  
Pre-treatment with Tf also protected against the early iron imbalance induced by light exposure, as 
detected on iron-related genes expression 1 day, and on iron retinal tissue staining 3 days after light 
exposure (Figure 5). Indeed, the retinal expression of iron-related proteins regulated through the 
IRP/IRE system, dependent on the intracellular iron status, was modified rapidly during light exposure 
(25). Here, we propose that pre-treatment with Tf avoids iron retinal overload through the down-
regulation of TfR1, Fpn, ferritins, and Dmt1 mRNA. Similarly, oral deferiprone and deferoxamine 
regulated Hmox1, TfR1 and ferritin expression in models of retinal degeneration (19-21, 46-47). Tf 
exerted a much stronger regulation of other iron-related gene expressions, Tf, Cp, HFE, and HJV, 
which do not depend on IRP/IRE systems. Hepcidin is a peptidic hormone synthesized in the retina 
that enhances ferroportin proteolysis under iron excess and inflammation, decreasing iron released 
(51-52). Its transcription is controlled by several signaling pathways, including Hemojuvelin 
(HJV)/BMP-6, IL6 and TfR2/HFE (53-54). Previously, Hadziahmetovic M. et al. demonstrated that 
IVT injection of Tf rapidly activated ERK1/2 signaling pathways through Tf/TfR2/HFE binding, 
which reduced iron export (55). One day after light exposure, Hfe, TfR2 and Hjv expression were 
down-regulated in the retina. This may decrease Hepcidin transcription and enhance iron release and 
PR death. The IVT injection of Tf prevented the light-induced Hfe down-regulation, which potentially 
enhanced the TfR2-HFE-Hepcidin pathway, and thus decreased iron exportation from cells. The role 
of TfR2 in iron metabolism is not fully understood, and its intracellular regulation, known to be 
independent of IRP/IRE system is not well characterized (56). In the retina, TfR2 is expressed in all 
nuclear layers, Tf injected co-localized with TfR2 in IPL, ONL and inner segments (Figure 1D-E). 
Recently, Wysokinski et al. showed an association between a polymorphisms of the TfR2 gene and the 
occurrence of AMD in obese patients (57). And Tf neuroprotective effect has also been demonstrated 
to depend on TfR2 binding (58-60). Thus, the local delivery of Tf, not only binds toxic free iron but 
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exerts a complex and interesting regulation of several proteins involved in retinal iron trafficking, 
resulting in a further reduction of iron-mediated oxidative toxicity.  
Another mechanism of Tf neuroprotective effects on light-induced retinal degeneration is 
related to the regulation of retinal inflammation. Studies already demonstrated that Tf modulated the 
cytokines profile in animal models of inflammation (61-62) and reduced the ageing-associated 
immunologic decline in mice (63). Tf was also shown to be efficient in an ocular model of intraocular 
inflammation (64). In our model, the intense cold white LED exposure induced an early retinal 
expression of genes involved in MC/macrophages recruitment (day 1) (Ccl2, Ccl17, Ccl12, Ccr2, 
Ccr4, and Il1a). This was followed by the massive infiltration of activated Iba1+ cells in the outer 
retina at 3 days (65-66) and the possible recruitment of circulating monocytes attracted by molecules 
up-regulated in the illuminated retina (Csf1, CD14, Interleukins, Toll-like receptors group, Cxcl 
chemokines and Cxcr receptors family genes) (67). Tf treatment induced a reduction of CD68 
intensity staining in Iba1 positive cells (Figure 7F) suggesting deactivation of MC/macrophages in the 
retina, known to be neurotoxic for PR and RPE cells (68-70). Tf also reduced retinal inflammation by 
the up-regulation of the anti-inflammatory cytokines Il1rn and Il9 (71) and the down-regulation of pro-
inflammatory cytokines Ccl1, Il1rap, Il22, Il23r (72-73). This supports an additional neuroprotective 
mechanism of Tf in relation with inflammatory responses. In this experiment, the modulation of 
cytokines profile expression paralleled the iron-related genes modification and the exact relation 
between these two mechanisms remains to be studied.   
 
 There are a number of considerations to use local delivery of iron chelator in a context of 
retinal disorders such as dry AMD. Beyond retinal protection, PR preservation in deleterious condition 
such as iron overload and chronic PR loss needed to be investigated. In this study, we showed that Tf 
not only protected the retina prior to light-exposure but was still partially effective after light exposure. 
Mechanisms could include reduction of reactive oxygen species production, iron accumulation, and 
lipids peroxydation. The therapeutic potential of Tf is also suggested by its ability to “clear” the outer 
retina and RPE from accumulated iron (Figure 11). Thus Tf could be adminstered not only for 
prevention but also to delay ongoing retinal degeneration. Because the half-life of Tf was short, and 
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retinal degeneration diseases are chronic diseases needing treatment over long period, a non-viral gene 
transfer technique was used to produce Tf locally in a sustained manner. The ciliary muscle 
electrotranfer of a plasmid encoding Tf not only showed a significant effect preventing PR 
degeneration in the acute light-induced retinal degeneration model (Figure 10 C-D) but also 
demonstrated a protective effect in a genetic model of slow retinal degeneration, the P23H rat (Figure 
10 E-F). This indicates that the slow and continuous intraocular release of Tf may very likely be 
beneficial to treat progressive retinal degeneration diseases.  
 
CONCLUSION 
 Many strategies are being developed to delay retinal degeneration and proving their efficacy in 
clinical trials is a real challenge. Whatever the cause of retinal degeneration, oxidative stress is 
involved in PR death and, in this context, iron neutralization is one of the strategies present in all 
neurodegenerative diseases. However, due to the redox activity of iron, it is important to consider 
whether iron chelators can provide the cellular specificity required to remove excess of iron from the 
appropriate tissue, without affecting systemic iron homeostasis. Here, we demonstrated that the local 
administration of Tf, the endogenous iron chelator naturally present in the eye, responded to this 
criteria. We showed that Tf protects PR against intense cell-death and preserves retinal functions 
through several mechanisms: oxidative stress, iron homeostasis balance, inflammation control and 
reduction of apoptosis. Therefore, we propose local ocular Tf administration as a high benefit/risk 
ratio therapeutic candidate to be evaluated to limit PR cell death in patients and with further potential 
applications including degenerative retinal diseases such as dry AMD.  
 
METHODS 
Animals  
Animals were fed with a standard laboratory diet and ad libitum tap water in a temperature-controlled 
room at 21-23°C. The cyclic light environment consisted of 12 hours light per day (6am-6pm). 
Animals were sacrificed by carbon dioxide inhalation. All experimental procedures in rats were 
submitted and approved by the local ethics committee European Council Charles Darwin, University 
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Paris Descartes. Experiments were performed in accordance with the Association for Research in 
Vision and Ophthalmology (ARVO) statement for the use of animals in Ophthalmic and Vision 
Research. 
 
Photic injury  
During the 3 weeks prior to light exposure, to reduce PR sensibility variability between rats, Wistar 
rats (7 to 10-months old) (Janvier laboratory, Le Genest St Isle, France) were adapted in ventilated 
cages at the bottom rows of the rack, where the level of light was controlled below 250 lux (74). 
The day before light exposure, rats were dark-adapted 18 hours from 6 pm. The next day, pupils were 
dilated with 1% atropine (Alcon, Norvartis, Rueil Malmaison, Fr) under dim light, and rats were 
isolated in separate cages containing enough food for one day. Then light-exposure was performed 
with commercial cold white LED panel generating 2,300 lumens during 24 hours. The LED panel was 
placed above 8 transparent cages, placed on white surfaces, leaving enough space for air circulation 
and constant temperature maintenance at 23°C. The luminance measured at the rats’ eyes position was 
6,500 lux (Photometre DT-8809A, CEM, China). After light exposure, rats were replaced under cyclic 
light (12h/day, 250 lux) for 1, 3, 8 or 16 days. Control animals were also dark adapted, and then 
returned to rearing cyclic light conditions.  
Rats were randomly separated into 3 groups (n= 4-5 rats per group): a control group not exposed to 
light and untreated (NLE), a group treated with intravitreous injection of sterile saline buffer (BSS, 
Bausch and Lomb, Montpellier, Fr) and exposed to light (BLE), and a group treated with an 
intravitreous injection of human Tf solution and exposed to light (TfLE).  
Intravitreal injections were performed after dark adaptation period under dim red light, or after light 
exposure under normal light condition. Lyophilized apotransferrin (iron free transferrin (Tf)) isolated 
from human plasma was dissolved in sterile BSS solution at a concentration of 48mg/ml (T5391, 
Sigma Aldrich Chemical Co, Saint-Quentin en Yvelines, Fr). Rats were anesthetized using 
intramuscular injection of 35:25 mix of ketamine (Virbac, Carros, Fr) and xylazine (Bayer, Lyon, Fr) 
(1ml/100mg) and intravitreal injections (5µl,) were performed in inferior quadrant of both rat eyes 
using a 30-gauge needle under an operating microscope. This content was determined as the most 
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efficient to protect photoreceptors (data not shown).  Rats were sacrificed at different time points after 
light exposure. For in vivo analysis and histology, rats were examined or sacrificed 8 or 16 days after 
light exposure. Additional time points were used for immunohistochemistry and RT-qPCR at 1, 3 or 8 
days after light exposure.  
 
Kinetic of transferrin eye distribution after intravitreal injection 
At 6, 24 hours and 7 days after intravitreous injection of apotransferrin (5µl at 48mg/ml in BSS; 
240µg), rats were sacrificed and eyes were enucleated, rinsed in 0.9% NaCl and dried. Ocular media 
and tissues were separated: aqueous humor and vitreous, cornea, iris/ ciliary body, neural retina, and 
RPE/choroid/sclera (eyecup). Retina and eyecups were analyzed individually whilst vitreous and 
aqueous humor from same eyes were pooled. Tissues were incubated in lysis buffer [15 mM Tris, pH 
7.9, 60 mM KCl, 15 mM NaCl, 2 mM EDTA, 0.4 mM phenylmethylsulphonyl fluoride (PMSF) 
(Perbio Science, Brebiers, Fr)]. After four freeze/thaw cycles, lysates were centrifuged at 5,000g for 
10 min and supernatants were stored at –20°C. Ocular fluids were diluted to a sufficient volume for 
assay. Human Tf was quantified by an antibody-sandwich ELISA as described (14).  
 
Immunohistochemistry  
Freshly enucleated eyes (n=3-4 per time point) (superior pole tagged with suture) were fixed for 2 
hours with 4% paraformaldehyde  (PAF, Inland Europe, Conflans sur Lanterne, Fr) in 1X phosphate-
buffered saline (PBS, Gibco distributed by Life Technologies), washed with PBS, infiltrated in 
gradients sucrose series and then, mounted in Tissue Tek O.C.T. (Siemens Medical, Puteaux, Fr).  
Immunohistochemistry was performed on 10µm-thick sections as previously described (14, 25). 
Cryosections were incubated with different primary antibodies: rabbit polyclonal anti-Tf receptor 1 
(Serotec, Oxford, UK), rabbit polyclonal specific for the High and Light subunits of Ferritin (P. 
Santambrogio); rabbit anti-cellular retinaldehyde binding protein (CRALBP; J. Saari); rabbit anti-
RPE65 (AbCys, Courtaboeuf, Fr); rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1, Wako 
Pure Chemical Industries, Neuss, Germany); mouse anti-CD68 (Bio-Rad AbD Serotec GmbH, 
Colmar, Fr); goat anti- Tf receptor 2 ( Genetex, Euromedex, Souffelweyersheim, Fr). Rods and cones 
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were respectively labeled with anti-rhodopsin (Rho4D2, R.S. Molday) and peanut agglutinin 
conjugated with fluorescein isothiocyanate (Sigma). Control sections were incubated with rabbit non-
immune serum (Invitrogen, Cergy Pontoise, Fr) or without primary antibodies. The corresponding 
Alexa–conjugated secondary antibodies (Invitrogen) were used to reveal the primary antibodies, and 
sections were counterstained with 4.6-diamidino-2-phenylindole (DAPI; Sigma). The sections were 
viewed with a fluorescence microscope (BX51, Olympus, Rungis, Fr) or confocal microscope (LSM 
510 laser scanning microscope Zeiss, Carl Zeiss, Le Pecq, Fr) and photographed using identical 
exposure parameters for all samples to be compared.  
Quantification of cones number 7 days after the end of light-exposure was realized throughout the 
superior pole of retinal sections and reported to control rats as 100%. Microglia cells activation 3 days 
after end of light-exposed was determined in outer plexiform layer, outer nuclear layer and segments 
layers, identified after DAPI nuclei stain. Measurement of microglia/macrophages staining was 
performed on pictures (60X) taken in the overall retina with same exposure time. The rapport of CD68 
intensity staining to total microglia cells revealed by Iba1 intensity staining was measured with ImageJ 
software. 
 
Histology and outer nuclear layer thickness measurement 
Oriented ocular globes were fixed with 4% PAF, 0.5% glutaraldehyde (LADD, Inland Europe, Fr) in 
PBS for 2 hours. After fixation, samples were washed, dehydrated and transferred into the infiltration 
solution of the Leica Historesin embedding kit (Leica, Nanterre, France) over night at 4°C. Samples 
were embedded in resin (Leica) and 5 µm thick sections passing through the optic nerve head were 
prepared along the superior and inferior pole of the eye using a microtome (Leica), stained with 1% 
Toluidin Blue solution. Sections were observed on a Leitz microscope and photographed with a Leica 
camera. Thicknesses of outer nuclear layer (ONL) were measured every 500 µm using Visilog 5.3 
software (Noesis, Courtabouef, Fr). Histological sections measurements were performed across the 
whole retina, considering the inferior pole to 0 from -4,000µm of optic nerve and superior pole to 0 
from 4,000µm of optic nerve. Thickness profiles along the retina were generated by averaging, for 
each distance, the values obtained for all eyes treated similarly to give a single value per group.  
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Optical Coherence Tomography 
For in vivo analysis, rats were anesthetized, pupils were dilated and pictures of retinas of both rat eyes 
were performed at superior pole using spectral domain OCT (SD-OCT; Spectralis device; Heidelberg) 
adapted for small animal eyes. Each volume scan consisted of at least 100 B-Scans recorded at 30° 
field of view centered on the superior pole, which were used to measure retinal thickness across the 
scanned retinal area.  
 
Electroretinography 
Full-field ERG responses were recorded 16 days after the end of light exposure. Rats were dark-
adapted over a period of 18 hours – for scotopic recordings – and anesthetized by an intramuscular 
injection of a mixture of ketamine and xylazine. The cornea was desensitized with a drop of 
oxybuprocaine (Novesine© Novartis Ophthalmics, Basel, Switzerland) and the pupils were dilated 
with a drop of tropicamide (Tropicamide©, Novartis Ophthalmics). Gold wire ring electrodes were 
placed on the corneas of both eyes and stainless steel needle electrodes inserted into the forehead 
served as working electrodes and references electrodes, respectively. A needle was subcutaneously 
inserted at the base of the animal tail for grounding. All these manipulations were performed under 
dim red light, without bringing the animal into ambient light after dark adaptation. Measurements were 
performed simultaneously in both rat eyes using the commercial Ganzfeld VisioSystem device (Siem 
Biomedicale, Nîmes, Fr). For scotopic electroretinograms in the dark-adapted state, flash intensities 
ranged from 0.0003 to 10 cd.s/m2. Five flashes per stimulation intensity were applied at a 0.5 Hz-
frequency, and corresponding responses were averaged. Flash duration was 10ms (–30 to 0 dB) except 
for 10 cd.s/m2 (0 dB) it was 30ms. Following the scotopic recordings, a rod-suppressing background 
light of 25 cd.s/m2 was turned on for 10 minutes. A cone-stimulating light flash was then applied, the 
light intensity being 10 cd.s/m2 (flash duration 79 ms), for photopic ERGs recording. Mixed (rods + 
cones) ERG measurements were performed simultaneously on both eyes, with flash intensity of 3 
cd.s/m2, flash duration of 40 ms, and the amplifier set to 0.5 Hz. Five responses were averaged. 
Amplitudes of a-waves (negative waves) were measured from the baseline to the bottom of the a-wave 
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trough, and b-wave amplitudes (positive waves) were measured from the bottom of the a-wave trough 
to the peak of the b-wave. Implicit times of the a- and b- waves were measured from time of stimulus 
to peaks. Results were expressed in microvolts (µV) for amplitudes and milliseconds (ms) for implicit 
times. The data obtained from each eye belonging to the same experimental group were averaged. 
 
RT-PCR Inflammation-focused genes array and data analysis  
Neural retinas were isolated on ice and directly frozen until RNA isolation. Total RNA was isolated 
with RNeasy mini kit (Qiagen, Courtaboeuf, Fr) according to the manufacturer’s protocols. RNA 
concentration, purity, and integrity were determined with an Agilent Bio-analyzer. All RNA used had 
RNA integrity number superior to 8. First-strand cDNA was generated by reverse transcription using 
0.7µg total RNA and the RT2 First Strand Kit (Qiagen). Genomic DNA was removed on RNeasy 
columns and before reverse transcription according to the manufacturer’s protocols. Expression of 84 
inflammatory-related genes and 5 housekeeping genes were evaluated in a 96-well plate (including 
five housekeeping and seven control genes) by the Rat Inflammatory-Autoimmunity RT2 Profiler 
PCR Array (PARN-077Z, SABiosciences, Qiagen). Gene arrays were processed according to the 
manufacturer’s instructions. Each PCR reaction was performed following manufacturer’s instructions, 
and dissociation curves were performed to control product of amplification. The threshold for 
calculating cycle threshold (Ct) values was calculated automatically using RQ software 
(SABiosciences). A fixed threshold was assigned manually, as suggested by the manufacturer. The 
relative expression of each gene was calculated using the ∆∆Ct method. Ct values were analyzed with 
Web-Based PCR Array Data Analysis tools: (http://www.sabiosciences.com/pcr/arrayanalysis.php, 
SABiosciences) to determine the best housekeeping gene (Rplp1), the fold change and p value of each 
gene (t-test Student). Fold changes ≥ ±2-fold were defined as biologically relevant changes.  
 
In vivo ciliary muscle electroporation of a plasmid encoding transferrin in rats 
Plasmids construction 
Human Tf cDNA was extracted by NotI digestion from pCMV6-hTf plasmid (Origene, Rockville, 
USA), and the 2.5kb product was then ligated into a NotI digested pVAX1 fragment (Life 
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Technologies), downstream of a cytomegalovirus-β promoter, to give pVAX1-Tf. pVAX1 empty was 
used as a negative control in all experiments. All plasmids were amplified in Escherichia coli bacteria 
and endotoxin-free prepared (EndoFree Plamid Kit; Qiagen, Courtaboeuf, France). Plasmids were 
diluted in endotoxin-free water containing 77 mM of NaCl (half saline) (saline, NaCl 0.9%, Versol, 
Laboratoire Aguettant, Lyon, Fr) as previously described (37). The concentration of DNA was 
determined by spectroscopy measurements (optical density at 260 nm). 
In vivo electroporation of the rat ciliary muscle 
Wistar adult males rats came from Janvier Laboratory. P23H-line 1 rats (40) were kindly provided by 
Mathiew Lavail (UCSF, Scool of Medecine, Beckman Vision Center), breeding at homozygous. 
Wistar rats (Janvier laboratory) were used as control. Rats were anesthetized as described, before 
ciliary muscle electrotransfer (ET). Thirty micrograms of plasmid (pVAX1, pVAX1-Tf), in a total 
volume of 10 µl, were injected in the ciliary muscle using a 30-gauge disposable needle (BD Micro-
Fine syringe, NM Médical, Asnière, Fr) transsclerally posterior to the limbus then electric pulses were 
delivered as described (37). Adult Wistar rats were sacrificed for ELISA Tf quantification in ocular 
media and tissues 3 days after ET and for retinal histology analysis 12 days after ET. For light 
experiment, ET were realized 3 days before light protocol realized as described above, and rats were 
sacrificed 8 days later. P23H rats were submitted to ET at 4 weeks of age (an age preceding major 
onset of PR loss in dystrophic rats), and killed at 8 weeks of age. All eyes were managed as described 
previously for histological analysis. ONL thickness were measured every 500µm of each pole the 
retina and values were averaged. Mean of ONL thickness at superior pole was representative of both 
poles and represented on figures.   
Statistical analysis 
Results are presented as mean ± Standard error on the mean (SEM). Analysis were performed using 
GraphPad Prism 5 software. Normal distribution of data was checked by the Shapiro–Wilk test. 
Comparisons between 2 groups were analyzed by unpaired two-tailed Student's t-test, and multiples 
comparisons by one-way ANOVA followed by Bonferroni post-test as appropriate. Non‐normally 
distributed were analysed using nonparametric Kruskal–Wallis test. p<0.05 was considered 
statistically significant.  
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LEGENDS 
Figure 1: Time-related distribution of transferrin after intravitreal injection in normal rats.  
(A-E) Adult Wistar rat received one intravitreal injection of transferrin (Tf) labeled with fluorochrom 
Alexa 488 (green). (A) Two hours after injection, Tf-Alexa 488 (left) co-localized (right) with Müller 
glial cells stained with anti-cellular retinaldehyde-binding protein (CRALBP) antibody (middle). (B-
C) Higher magnification revealed Tf-Alexa on apical side of retinal pigment epithelium revealed with 
anti-RPE65 antibody (red) (B), and at photoreceptors segments layers stained with rhodopsin (red, 
asterisk) (C). (D) Tf-Alexa merged (yellow) with transferrin receptor 1 (red) in synaptic layers. (E) Tf-
Alexa co-localized with transferrin receptor 2 (red) in inner segments, outer nuclear layer and inner 
plexiform layer. (F) Six hours after injection, Tf-Alexa was in overall retina and additionally detected 
in choroid (Ch) vessels. (G-H) Transferrin levels were quantified in posterior segment tissues (G) and 
ocular fluids (H) by ELISA assay, 6 and 24 hours after Tf injection. All values are represented as 
mean± SEM. Student’s t-test; n=3-4 rats per time; ** p=0.0032; *** p<0.0001.  
Ch: Choroid; GCL: Ganglion cell layer; INL: Inner nuclear layer; IPL: Inner plexiform layer; IS: Inner 
segment; ONL: Outer nuclear layer; OPL: Outer plexiform layer; OS: Outer segment; RPE: retinal 
pigment epithelium. Scale bars A, C, D-F: 50µm; B: 20µm. Nuclei stained with DAPI (blue). 
 
Figure 2: IVT injections of transferrin have no retinal toxicity.  
(A) In vivo retinal structure recorded by optical coherence tomography (OCT) 7 days after first 
transferrin (Tf) IVT injection (D7) and 7 days after the second Tf injection (D14) in rats, demonstrated 
no retinal histological modifications. (B) Measurement of outer nuclear layer (ONL) from OCT 
pictures in control not injected rats and rats injected once (D7) or twice (D14) with Tf. (C) Pictures of 
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historesin semi-thin sagital retinal sections 7 days after the second Tf injection. (D) Mean ONL 
thickness measured on sections crossing the optic nerve in overall retina of control rats and twice Tf-
injected rats.  
All values are represented as mean ±SEM; Student’s t-test; n=4 eyes per group; ns= not significant.  
GCL: Ganglion cell layer; INL: Inner nuclear layer; IPL: Inner plexiform layer; IS: Inner segment; 
ONL: Outer nuclear layer; OPL: Outer plexiform layer; OS: Outer segment; RPE: retinal pigment 
epithelium. Scale bar A: 200µm; C: 100µm. 
 
Figure 3: Intravitreal injection of transferrin protects rat retina against light-induced retinal 
degeneration.  
Transferrin (Tf) was injected in rats before a 24-hours continuous light exposure, analyses were 
performed after 8 days. (A) In vivo optical coherence tomography (OCT) images showed a reduction 
of outer nuclear layer (ONL) thickness in BLE rats compare to NLE and TfLE rats. (B) ONL thickness 
of superior pole (500 to 3,000µm from optic nerve) measured on OCT pictures in intervals of 500µm, 
in NLE, BLE and TfLE rats. (C) Retinal semi-thin sections at the superior pole showed important 
photoreceptor nuclei layer (ONL) degeneration in BLE rats as compared to control (NLE) or TfLE 
rats. (D) Measures of ONL thickness, with intervals of 500µm, across the entire retina show that Tf-
treatment significantly protect photoreceptors nuclei layer thickness as compared to BSS treatment. 
BLE: Rats injected with BSS and exposed to light (red lines); NLE: Control rats neither injected nor 
exposed to light (black lines); TfLE: Rats injected with human Tf and exposed to light (blue lines). All 
values are represented as mean ±SEM; One-way ANOVA, followed with Bonferroni post-test. n=8-10 
eyes per group; significative differences (***p<0.001) were observed between TfLE and BLE. All 
statistic analyses can be found in Supp. Table 1. GCL: Ganglion cell layer; INL: Inner nuclear layer; 
IS: Inner segment; ONL: Outer nuclear layer; OS: Outer segment; RPE: retinal pigment epithelium. 
Scale bars: A: 200µm, C: 100µm. 
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Figure 4: Transferrin decreases light-induced photoreceptors apoptosis and perserves visual 
activities.  
(A) TUNEL staining (red) and (B) fluorescence intensity quantification at the photoreceptors nuclei 
layer, 1 day after light exposure show a reduction of apoptosis in TfLE compared to BLE retinas. 
Mann-Whitney test; n=3-4 retinas per group; *p=0.0201. (C) Rods immunostaining (green, top panel) 
and cones lectin staining (green, bottom panel, arrows) in rats at 8 days reflect the integrity of TfLE 
photoreceptors. (D) Scotopic electroretinogram, specific to rod-driven responses, was recorded 16 
days after light exposure. Light (red lines) induced a collapse of a-waves (dotted lines) and b-waves 
(solid waves) amplitudes. Those amplitudes were preserved in TfLE (blue lines) and reached nearly 
50% of NLE values (black lines). One-way ANOVA, followed with Bonferroni post-test. n=8 eyes per 
group; significative differences (*p<0.05, **p<0.01) were observed between TfLE and BLE. (E) 
Photopic ERG was recorded after saturation of rods to obtain specific cone response. The amplitude 
(left part) and the implicit time (right part) of the b-wave are represented on the graph. While the light 
induced reduction of the b-wave amplitude was not prevented by the injection of Tf (blue bar), the 
treatment normalized the b-wave implicit time (shaded blue bar). One-way ANOVA, followed with 
Bonferroni post-test. n=8 eyes per group; significative differences (*p<0.05, **p<0.01). (F) 
Quantification of cones on superior pole. BLE group and TfLE are expressed relative to the control 
group (NLE). Percentage of cones reduced in BLE rats was partially preserved in TfLE rats. Mann-
Whitney t-test; n= 3 eyes per group; * p<0.05. 
BLE: Rats injected with BSS and exposed to light (red); NLE: Control rats neither exposed to light, 
neither injected (black); TfLE: Rats injected with human Tf and exposed to light (blue ). All values are 
represented as mean ±SEM. (Complete statistic analysis for D and E can be found in Supp. Table 1. 
INL: Inner nuclear layer; ONL: Outer nuclear layer.  A, C: Nuclei stained with DAPI. Scale bars A: 
100µm; C: 20µm.  
 
Figure 5: Transferrin treatment controls iron metabolism.  
(A) Quantitative PCR of iron-related genes mRNA normalized with Ribosomal Protein P1 (Rplp1) 
mRNA on neural retina one day after light exposure. Transcripts related to transport (Tf and TfR1), 
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storage (Ferritin Heavy chain (FtH) and Light chain (FtL)), export (Divalent metal transporter 1 
(Dmt1), Ferroportin (Fpn), Ceruloplasmin (Cp)) and regulation of iron (TfR2, Human 
hemochromatosis protein (Hfe), Hemojuvelin (Hjv)) were modified following light exposure when 
comparing BLE to NLE rats. When comparing TfLE to BLE retinas, Tf-treatment modulated  the 
expression of several of these iron-related mRNAs. All values are represented as mean ±SEM; One-
way ANOVA, Bonferroni post-test; n=5-6 neural retinas; * p<0.05; ** p<0.01; *** p<0.001, ns= not 
significant. (B-D) Immunohistochemistry of ferritins and transferrin receptor 1 on retinal sections 3 
days after light exposure. Heavy chain (B) and light chain (C) ferritins and transferrin receptor 1 
staining (D) were conserved in TfLE rat retinas (right column) as compared to NLE rat retinas (left 
column), whereas proteins staining intensities were modified in BLE rat retinas (central column). 
Nuclei stained with DAPI (blue). Scale bar B-D: 100µm. (E) Iron labeling on retinal cryosections 
demonstrate iron accumulation in outer retinas of BLE rats at 8 days after light exposure. TfLE retinas 
iron staining was similar to NLE rat retinas. Scale bar: 100µm. (F) Total non-heme iron quantification 
in the retinas demonstrate that Tf prevented free iron content to increase after light exposure. All 
values are represented as mean ±SEM; Kruskal-Wallis, Dunn post-test; n=3-4 retinas; * p<0.0.5.  
BLE: Rats injected with BSS and exposed to light (red); NLE: Control rats neither injected nor 
exposed to light (black); TfLE: Rats injected with human Tf and exposed to light (blue).  
 
Figure 6: Transferrin inhibits light-induced oxidative stress.   
Heme oxygenase 1 (Hmox1) mRNA expression related to control gene Ribosomal Protein P1 (Rplp1) 
was determined in neural retina one day after light-injury. While light exposure drastically increases 
Hmox1 gene expression (BLE group), Tf injection significantly reduced this increase (TfLE group). 
All values are represented as mean of fold change ±SEM. One-way ANOVA, Bonferroni post-test; 
n=5-6 retina per group; *p<0.05; *** p<0.001; ns = not significant. BLE: Rats injected with BSS and 
exposed to light (red bar); NLE: Control rats neither injected nor exposed to light (black bar); TfLE: 
Rats injected with human Tf and exposed to light (blue bar).  
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Figure 7: Transferrin injection manages inflammatory cells responses.  
(A) In control group, microglia cells (arrow) anti-ionized calcium binding adaptor molecule 1 (Iba1) 
positive were localized in inner retina and negative for anti-CD68, marker of activation. (B-G) 
Microglial/macrophages cells migrated in photoreceptors layer (arrows) after light-exposure as 
observed 1 (B-C), 3 (D-E) or 8 (G-H) days after light period. (D2-E2) Higher magnification of 
corresponding area delimited in outer retina of D and E revealed more Iba1+/CD68+ co-staining in 
BLE rats than in TfLE rats. (F) Quantification of CD68 positive cells staining were reported to Iba1 
cells intensity staining measured in outer retina 3 days after light period. Microglial/macrophages 
activation after light exposure was reduced with Tf injection. All values are represented as mean± 
SEM. Mann-Whitney test; n=3 eyes per time; *p=0.0104. (G-H) At day 8, in BLE rat retinas, 
microglial/macrophages cells accumulated in outer retina (arrows, G) compared to TfLE retinas 
(arrowheads, H).  
Rats injected with BSS and exposed to light (red bar); TfLE: Rats injected with human Tf and exposed 
to light (blue bar). Scale bar A-H: 100µm; D2-E2: 50µm.   
 
Figure 8. Volcano plots of  mRNAs regulated by transferrin in light exposed retinas. 
Volcano plot of 84 differentially expressed genes in light exposed retinas treated with Tf relative to 
control treatment (n = 5-6 per group) according to their p-value versus fold change. Highest fold 
change expression (|Log2(fold change)| ≥ 2) are colored. Significant differences were determined with 
Student’s t-test (p<0.05; n=5-6 retinas per group). BLE: Rats injected with BSS and exposed to light 
(red bar); TfLE: Rats injected with human Tf and exposed to light (blue bar). 
 
Figure 9: Intravitreal injection of transferrin partially protects degenerated retina.  
After a dark adaptation period, rats were placed under a 24-hour intense light treatment. We 
subsequently injected Tf or BSS solutions via IVT, and sacrificed them 8 days later. (A) Historesin 
blue-stained sections on inferior pole demonstrate partial preservation of retina structure with Tf 
injection. ONL: Outer nuclear layer. Scale bar: 100µm. (B) ONL thickness measurement throughout 
the retina, every 500µm, showed protective effect of Tf only in the inferior pole. All values are 
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represented as mean ±SEM; TfLE retinas were compared to BLE at each different distance from the 
optic nerve with one-way ANOVA, Bonferroni post-test; n=8 eyes per group; *** p<0.001. BLE: Rats 
injected with BSS and exposed to light (red line); NLE: Control rats neither injected nor exposed to 
light (black line); TfLE: Rats injected with human Tf and exposed to light (blue line). 
 
Figure 10: Non-viral gene therapy for local transferrin production preserves photoreceptors in 2 
models of retinal degeneration.  
 (A) Histology of the retina following electrotransfer of empty plasmid (pVAX1) or containing cDNA 
of transferrin (pVAX1-Tf). (B) Mean ONL thickness evaluated on historesin semi-thin retinal sections 
in control rats (black bar), and 12 days after ET of pVAX1 (red bar) or pVAX1-Tf (blue bar) in rats. 
ET and substained production of Tf had no deleterious effect on retina structure. (C) Historesin 
sections (D) and mean of ONL thickness of rats electrotransfered with pVAX1 (red bar) or pVAX-Tf 
(blue bar), submitted to light-exposure (LE) 3 days after, and sacrificed 8 days later. Control rats not 
ET but exposed to light are represented with black bar (control, LE). (E) Historesin sections and mean 
of ONL thickness (F) of P23H rats retinas (black bar), model of slow retinal degeneration, 
electrotransfered at 4 weeks of age with pVAX1 (red bar) or pVAX-Tf plasmids (blue bar), and 
sacrificed 4 weeks later. Scale bar: 100µm; All values are represented as mean ±SEM; One-way 
ANOVA, Bonferroni post-test; n=6-10 eyes per group; *p<0.05; *** p<0.001; ns=not significant.  
 
Figure 11: Treatments with transferrin remove retinal iron deposits in a mouse model of iron 
overload.  
(A) Iron staining (blue) by Perls method in the RPE of 32 weeks-old mice Bmp6-/- (control), 
intraperitoneally (IP) injected with BSS or Tf. Sections were counterstained with nuclear red. RPE: 
Retinal pigment epithelium. Scale bar: 10µm. (B) Quantification of iron staining in retinal pigment 
epithelium (RPE) in 32 weeks-old Bmp6 KO mice (black bar), treated with Tf (blue bar) or BSS (red 
bar) by IP injections, 3 times per week for one month, or with a single intravitreal injection. All values 
are represented as mean ±SEM; Student’s t-test; n=4-6 retinas per group; *p=0.0475; **p=0.0035  
Table 1 
Gene Refseq 
 BLE / 
NLE 
p value 
TfLE / 
NLE 
p value 
Cytokines            
Chemokines            
Ccl2 NM_031530  19,50 0,0067 23,19 0,0278 
Ccl3 NM_013025  1,67 0,1277 2,01 0,0977 
Ccl4 NM_053858  1,36 0,6613 1,83 0,355 
Ccl5 NM_031116  -2,27 0,0642 -1,09 0,5834 
Ccl6 NM_001004202  1,16 0,4972 3,57 0,0241 
Ccl7 NM_001007612  141,29 0,0084 139,54 0,0669 
Ccl12 NM_001105822  39,93 0,021 33,79 0,0012 
Ccl20 NM_019233  1,33 0,6313 2,58 0,1097 
Ccl21 NM_001008513  -2,25 0,0956 -1,48 0,8691 
Ccl22 NM_057203  -1,22 0,5055 2,26 0,3109 
Ccl24 NM_001013045  -3,01 0,0994 -1,80 0,0031 
Cxcl1 NM_030845  3,31 0,0049 3,54 0,0742 
Cxcl3 NM_138522  4,10 0,0048 8,77 2,2E-05 
Cxcl5 NM_022214  -1,02 0,9667 2,43 0,1864 
Cxcl9 NM_145672  4,76 0,0126 13,72 0,0314 
Cxcl10 NM_139089  4,64 0,0395 4,44 0,0947 
Cxcl11 NM_182952  4,24 0,0032 3,85 0,0001 
 Interleukins            
Il1a NM_017019  11,67 0,1829 16,80 0,0426 
Il1b NM_031512  1,79 0,357 7,73 0,0593 
Il5 NM_021834  -9,09 0,0515 -3,33 0,1385 
Il6 NM_012589  3,83 0,4927 6,02 0,1943 
Il7 NM_013110  -1,62 0,2695 -2,23 0,1356 
Il9 NM_001105747  -1,05 0,881 3,61 0,0695 
Il10 NM_012854  -1,65 0,1272 -2,04 0,0637 
Il17a NM_001106897  -3,29 0,1357 -1,75 0,3971 
Il18 NM_019165  1,98 0,0103 2,52 0,0006 
Il22 XM_576228  -1,65 0,2752 -2,93 0,1197 
Il23a NM_130410  -2,17 0,0385 -2,11 0,0317 
 Others inflammatory molecules  
Cd401g NM_053353  3,90 0,7813 2,68 0,8795 
Crp NM_017096  -3,42 0,0818 -2,82 0,0687 
Csf1 NM_023981  3,39 0,0008 2,60 0,037 
Faslg NM_012908  -1,75 0,0865 -2,94 0,0198 
Ifng NM_138880  2,20 0,3781 -1,89 0,5869 
Kng1 NM_012696  -1,40 0,1172 -1,64 0,0822 
Lta NM_080769  -2,35 0,0972 -1,48 0,5197 
Tnf NM_212507  2,71 0,7748 2,48 0,7756 
Tnfsf14 XM_236794  9,88 0,0477 12,89 0,0604 
 Cytokines Receptors  
Ccr1 NM_020542  9,34 0,1125 17,14 0,1241 
Ccr2 NM_021866  20,61 0,1823 23,51 0,1025 
Ccr3 NM_053958  -2,61 0,2377 2,98 0,2298 
Ccr4 NM_133532  6,57 0,1385 8,53 0,0147 
Cxcr2 NM_017183  4,58 0,3733 18,44 0,2491 
Cd14 NM_021744  18,41 0,0422 23,18 0,008 
Il1r1 NM_013123  2,46 0,0073 2,34 0,0077 
Il1rap NM_012968  1,25 0,6099 -1,37 0,2529 
Il1rn NM_022194  4,84 0,2192 13,73 0,0729 
Il8ra NM_019310  1,07 0,8021 2,11 0,2735 
Il23r XM_001072576  2,70 0,0284 1,19 0,5756 
  Regulation of Inflammatory Response  
B2m NM_012512  3,05 1,6E-06 3,48 1,2E-05 
C3 NM_016994  2,27 0,1503 2,30 0,0478 
C3ar1 NM_032060  3,15 0,0933 4,23 0,0036 
Cebpb NM_024125  3,25 0,013 2,32 0,0351 
Itgb2 NM_001037780  3,12 0,0615 5,46 0,0038 
Sele NM_138879  2,41 0,0433 2,33 0,0979 
Nos2 NM_012611  -2,43 0,0476 -1,95 0,1874 
Nr3c1 NM_012576  -2,48 0,0354 -2,58 0,0294 
Tirap XM_001055833  -2,28 0,0782 -2,23 0,0819 
Tollip NM_001109668  -2,76 0,0443 -1,79 0,0866 
Table
Tlr1 NM_001172120  5,26 0,063 8,11 0,0103 
Tlr2 NM_198769  3,68 0,0904 5,41 0,0054 
Tlr3 NM_198791  3,36 0,0414 3,00 0,067 
Tlr5 NM_001145828  6,35 0,2831 2,49 0,4212 
Tlr7 NM_001097582  2,67 0,0582 2,27 0,0535 
Table1: Inflammatory genes name, RefSeq, functional grouping, and fold change with p value in 
neural retinas one day after light exposure.  
Results are presented as the average fold change in gene expression obtained in rats injected with BSS 
and exposed to light (BLE) compared to unexposed rats (BLE/NLE), and in rats injected with 
transferrin and exposed to light (TfLE) rats compared to NLE rats (TfLE/NLE). Transcripts up-
regulated (blue) and down-regulated (red) more than 2-fold were represented. Significant differences 
determined with Student’s t-test (p<0.05; n=5-6 retinas per group) were bold.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis Figures 
Parameters  
measured 
Groups Statistic comparisons 
NLE BLE TfLE 
NLE 
vs 
BLE 
NLE vs 
TfLE 
TfLE 
vs BLE 
O
C
T
 
3B 
ONL thickness at 
superior pole 
63.33 µm 
±0,43 
35.52 µm 
±3.35 
65.13 µm 
±0.85 
***  ns ***  
H
is
to
lo
g
y
 
3D 
ONL thickness at 
superior pole 
41.64 µm 
±1.77 
8.96 µm 
±1.20 
29.31 µm 
±1.68 
***  ***  ***  
3D 
ONL thickness at 
inferior pole 
39.3 µm 
±1.55 
23.25 µm 
±1.12 
36.14 µm 
±1.86 
***  ns *** 
E
le
ct
ro
re
ti
n
o
g
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p
h
y
 
S
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 4D 
a-wave amplitude 
ranging from -0.5 
to 0.47 
log(cd.s/m
2
) 
-90.29µV 
±8.45 
-15.71µV 
±2.2 
-49.83µV 
±3.35 
***  ** * 
4D 
b-wave amplitude 
ranging from -0.5 
to 0.47 
log(cd.s/m
2
) 
297.6µV 
±16.81 
43.83µV 
±1.5 
140.3µV 
±7.24 
***  ***  **  
P
h
o
to
p
ic
 
4E b-wave amplitude 
79.63µV 
±6.06 
40.88µV 
±9.89 
43.63µV 
±7.85 
***  * ns 
4F 
b-wave implicit 
time 
53.38ms 
±0.90 
61.88 ms 
±3.77 
57.13 ms 
±1.92 
* ns * 
 
Supplemental Table 1: Statistic analysis of histological and electrophysiological parameters of 
rats treated before light-exposure. 
Each line represents mean values of parameters measured in figure 3 and 4, and statistical analysis 
with one-way ANOVA, followed with Bonferroni post-test. n=8-10; *p<0.05; ** p<0.01; *** 
p<0.001; ns=not significant. BLE: Rats injected with BSS and exposed to light (red lines); NLE: 
Control rats neither injected nor exposed to light (black lines); TfLE: Rats injected with human Tf and 
exposed to light (blue lines). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table
  
 
Gene 
TfLE / 
BLE 
p value 
Cytokines     
Chemokines     
Ccl1 -2,75 0,335 
Ccl5 2,08 0,05 
Ccl6 3,09 0,047 
Ccl11 1,64 0,217 
Ccl20 1,94 0,291 
Ccl21 1,52 0,417 
Ccl22 2,75 0,244 
Ccl24 1,68 0,509 
Cxcl3 2,14 0,005 
Cxcl5 2,48 0,039 
Cxcl9 2,88 0,071 
Interleukins     
Il1b 4,33 0,086 
Il5 2,72 0,143 
Il6 1,57 0,278 
Il9 3,79 0,033 
Il17a 1,88 0,208 
Il22 -1,78 0,027 
Others inflammatory 
molecules     
Faslg -1,68 0,049 
Ifng -4,17 0,309 
Lta 1,59 0,322 
Receptors  
Ccr1 1,84 0,436 
Ccr3 7,78 0,113 
Ccr7 1,51 0,952 
Cxcr2 4,03 0,197 
Cxcr4 1,76 0,188 
Il1rap -1,72 0,011 
Il1rn 2,84 0,193 
Il8ra 1,98 0,042 
Il23r -2,27 0,044 
Signalisation 
Itgb2 1,75 0,204 
Tollip 1,55 0,268 
Tlr1 1,54 0,54 
Tlr5 -2,56 0,309 
 
Supplemental Table 2: Inflammatory genes expression regulated by transferrin treatment.  
Results are presented as the average fold change in gene expression obtained in rats injected with 
transferrin and light-exposed (TfLE) compared to those treated with BSS (TfLE/BLE). Only genes up-
regulated (blue) and down-regulated (red) more than 1.5 fold were represented. Significant differences 
determined with Student’s t-test (p<0.05; n=5-6 retinas per group) were bold. 
 
Figure 1: Time-related distribution of transferrin after intravitreal injection in normal rats.  
(A-E) Adult Wistar rat received one intravitreal injection of transferrin (Tf) labeled with fluorochrom 
Alexa 488 (green). (A) Two hours after injection, Tf-Alexa 488 (left) co-localized (right) with Müller glial 
cells stained with anti-cellular retinaldehyde-binding protein (CRALBP) antibody (middle). (B-C) Higher 
magnification revealed Tf-Alexa on apical side of retinal pigment epithelium revealed with anti-RPE65 
antibody (red) (B), and at photoreceptors segments layers stained with rhodopsin (red, asterisk) (C). 
(D) Tf-Alexa merged (yellow) with transferrin receptor 1 (red) in synaptic layers. (E) Tf-Alexa co-
localized with transferrin receptor 2 (red) in inner segments, outer nuclear layer and inner plexiform 
layer. (F) Six hours after injection, Tf-Alexa was in overall retina and additionally detected in choroid 
(Ch) vessels. (G-H) Transferrin levels were quantified in posterior segment tissues (G) and ocular fluids 
(H) by ELISA assay, 6 and 24 hours after Tf injection. All values are represented as mean± SEM. 
Student’s t-test; n=3-4 rats per time; ** p=0.0032; *** p<0.0001.  
Ch: Choroid; GCL: Ganglion cell layer; INL: Inner nuclear layer; IPL: Inner plexiform layer; IS: Inner 
segment; ONL: Outer nuclear layer; OPL: Outer plexiform layer; OS: Outer segment; RPE: retinal 
pigment epithelium. Scale bars A, C, D-F: 50µm; B: 20µm. Nuclei stained with DAPI (blue). 
Figure
Figure 2: IVT injections of transferrin have no retinal toxicity. (A) In vivo retinal structure recorded by 
optical coherence tomography (OCT) 7 days after first transferrin (Tf) IVT injection (D7) and 7 days 
after the second Tf injection (D14) in rats, demonstrated no retinal histological modifications. (B) 
Measurement of outer nuclear layer (ONL) from OCT pictures in control not injected rats and rats 
injected once (D7) or twice (D14) with Tf. (C) Pictures of historesin semi-thin sagital retinal sections 7 
days after the second Tf injection. (D) Mean ONL thickness measured on sections crossing the optic 
nerve in overall retina of control rats and twice Tf-injected rats. All values are represented as mean 
±SEM; Student’s t-test; n=4 eyes per group; ns= not significant. GCL: Ganglion cell layer; INL: Inner 
nuclear layer; IPL: Inner plexiform layer; IS: Inner segment; ONL: Outer nuclear layer; OPL: Outer 
plexiform layer; OS: Outer segment; RPE: retinal pigment epithelium. Scale bar A: 200µm; C: 100µm. 
 
Figure 3: Intravitreal injection of transferrin protects rat retina against light-induced retinal 
degeneration.  
Transferrin (Tf) was injected in rats before a 24-hours continuous light exposure, analyses were 
performed after 8 days. (A) In vivo optical coherence tomography (OCT) images showed a reduction of 
outer nuclear layer (ONL) thickness in BLE rats compare to NLE and TfLE rats. (B) ONL thickness of superior 
pole (500 to 3,000µm from optic nerve) measured on OCT pictures in intervals of 500µm, in NLE, BLE and 
TfLE rats. (C) Retinal semi-thin sections at the superior pole showed important photoreceptor nuclei layer 
(ONL) degeneration in BLE rats as compared to control (NLE) or TfLE rats. (D) Measures of ONL thickness, 
with intervals of 500µm, across the entire retina show that Tf-treatment significantly protect 
photoreceptors nuclei layer thickness as compared to BSS treatment. 
BLE: Rats injected with BSS and exposed to light (red lines); NLE: Control rats neither injected nor exposed 
to light (black lines); TfLE: Rats injected with human Tf and exposed to light (blue lines). All values are 
represented as mean ±SEM; One-way ANOVA, followed with Bonferroni post-test. n=8-10 eyes per group; 
significative differences (***p<0.001) were observed between TfLE and BLE. All statistic analyses can be 
found in Supp. Table 1. GCL: Ganglion cell layer; INL: Inner nuclear layer; IS: Inner segment; ONL: Outer 
nuclear layer; OS: Outer segment; RPE: retinal pigment epithelium. Scale bars: A: 200µm, C: 100µm. 
 
Figure 4: Transferrin decreases light-induced photoreceptors apoptosis and perserves visual activities.  
(A) TUNEL staining (red) and (B) fluorescence intensity quantification at the photoreceptors nuclei layer, 
1 day after light exposure show a reduction of apoptosis in TfLE compared to BLE retinas. Mann-Whitney 
test; n=3-4 retinas per group; *p=0.0201. (C) Rods immunostaining (green, top panel) and cones lectin 
staining (green, bottom panel, arrows) in rats at 8 days reflect the integrity of TfLE photoreceptors. (D) 
Scotopic electroretinogram, specific to rod-driven responses, was recorded 16 days after light exposure. 
Light (red lines) induced a collapse of a-waves (dotted lines) and b-waves (solid waves) amplitudes. Those 
amplitudes were preserved in TfLE (blue lines) and reached nearly 50% of NLE values (black lines). One-
way ANOVA, followed with Bonferroni post-test. n=8 eyes per group; significative differences (*p<0.05, 
**p<0.01) were observed between TfLE and BLE. (E) Photopic ERG was recorded after saturation of rods 
to obtain specific cone response. The amplitude (left part) and the implicit time (right part) of the b-wave 
are represented on the graph. While the light induced reduction of the b-wave amplitude was not 
prevented by the injection of Tf (blue bar), the treatment normalized the b-wave implicit time (shaded 
blue bar). One-way ANOVA, followed with Bonferroni post-test. n=8 eyes per group; significative 
differences (*p<0.05, **p<0.01). (F) Quantification of cones on superior pole. BLE group and TfLE are 
expressed relative to the control group (NLE). Percentage of cones reduced in BLE rats was partially 
preserved in TfLE rats. Mann-Whitney t-test; n= 3 eyes per group; * p<0.05. 
BLE: Rats injected with BSS and exposed to light (red); NLE: Control rats neither exposed to light, neither 
injected (black); TfLE: Rats injected with human Tf and exposed to light (blue ). All values are represented 
as mean ±SEM. (Complete statistic analysis for D and E can be found in Supp. Table 1. INL: Inner nuclear 
layer; ONL: Outer nuclear layer.  A, C: Nuclei stained with DAPI. Scale bars A: 100µm; C: 20µm.  
Figure 5: Transferrin treatment controls iron metabolism.  
(A) Quantitative PCR of iron-related genes mRNA normalized with Ribosomal Protein P1 (Rplp1) mRNA on neural retina one day after light 
exposure. Transcripts related to transport (Tf and TfR1), storage (Ferritin Heavy chain (FtH) and Light chain (FtL)), export (Divalent metal 
transporter 1 (Dmt1), Ferroportin (Fpn), Ceruloplasmin (Cp)) and regulation of iron (TfR2, Human hemochromatosis protein (Hfe), Hemojuvelin 
(Hjv)) were modified following light exposure when comparing BLE to NLE rats. When comparing TfLE to BLE retinas, Tf-treatment modulated  
the expression of several of these iron-related mRNAs. All values are represented as mean ±SEM; One-way ANOVA, Bonferroni post-test; n=5-6 
neural retinas; * p<0.05; ** p<0.01; *** p<0.001, ns= not significant. (B-D) Immunohistochemistry of ferritins and transferrin receptor 1 on 
retinal sections 3 days after light exposure. Heavy chain (B) and light chain (C) ferritins and transferrin receptor 1 staining (D) were conserved in 
TfLE rat retinas (right column) as compared to NLE rat retinas (left column), whereas proteins staining intensities were modified in BLE rat 
retinas (central column). Nuclei stained with DAPI (blue). Scale bar B-D: 100µm. (E) Iron labeling on retinal cryosections demonstrate iron 
accumulation in outer retinas of BLE rats at 8 days after light exposure. TfLE retinas iron staining was similar to NLE rat retinas. Scale bar: 
100µm. (F) Total non-heme iron quantification in the retinas demonstrate that Tf prevented free iron content to increase after light exposure. 
All values are represented as mean ±SEM; Kruskal-Wallis, Dunn post-test; n=3-4 retinas; * p<0.0.5. BLE: Rats injected with BSS and exposed to 
light (red); NLE: Control rats neither injected nor exposed to light (black); TfLE: Rats injected with human Tf and exposed to light (blue).  
 
Figure 6: Transferrin inhibits light-induced oxidative stress.   
Heme oxygenase 1 (Hmox1) mRNA expression related to control gene Ribosomal Protein P1 (Rplp1) was 
determined in neural retina one day after light-injury. While light exposure drastically increases Hmox1 gene 
expression (BLE group), Tf injection significantly reduced this increase (TfLE group). All values are represented 
as mean of fold change ±SEM. One-way ANOVA, Bonferroni post-test; n=5-6 retina per group; *p<0.05; *** 
p<0.001; ns = not significant. BLE: Rats injected with BSS and exposed to light (red bar); NLE: Control rats 
neither injected nor exposed to light (black bar); TfLE: Rats injected with human Tf and exposed to light (blue 
bar).  
Figure 7: Transferrin injection manages inflammatory cells responses.  
(A) In control group, microglia cells (arrow) anti-ionized calcium binding adaptor molecule 1 (Iba1) positive were 
localized in inner retina and negative for anti-CD68, marker of activation. (B-G) Microglial/macrophages cells 
migrated in photoreceptors layer (arrows) after light-exposure as observed 1 (B-C), 3 (D-E) or 8 (G-H) days after light 
period. (D2-E2) Higher magnification of corresponding area delimited in outer retina of D and E revealed more 
Iba1+/CD68+ co-staining in BLE rats than in TfLE rats. (F) Quantification of CD68 positive cells staining were reported 
to Iba1 cells intensity staining measured in outer retina 3 days after light period. Microglial/macrophages activation 
after light exposure was reduced with Tf injection. All values are represented as mean± SEM. Mann-Whitney test; n=3 
eyes per time; *p=0.0104. (G-H) At day 8, in BLE rat retinas, microglial/macrophages cells accumulated in outer retina 
(arrows, G) compared to TfLE retinas (arrowheads, H).  
Rats injected with BSS and exposed to light (red bar); TfLE: Rats injected with human Tf and exposed to light (blue 
bar). Scale bar A-H: 100µm; D2-E2: 50µm.   
Figure 8. Volcano plots of  mRNAs regulated by transferrin in light exposed 
retinas. 
Volcano plot of 84 differentially expressed genes in light exposed retinas treated 
with Tf relative to control treatment (n = 5-6 per group) according to their p-value 
versus fold change. Highest fold change expression (|Log2
(fold change)| ≥ 2) are 
colored. Significant differences were determined with Student’s t-test (p<0.05; n=5-
6 retinas per group). BLE: Rats injected with BSS and exposed to light (red bar); TfLE: 
Rats injected with human Tf and exposed to light (blue bar). 
Figure 9: Intravitreal injection of transferrin partially protects degenerated retina.  
After a dark adaptation period, rats were placed under a 24-hour intense light treatment. We subsequently 
injected Tf or BSS solutions via IVT, and sacrificed them 8 days later. (A) Historesin blue-stained sections on 
inferior pole demonstrate partial preservation of retina structure with Tf injection. ONL: Outer nuclear layer. 
Scale bar: 100µm. (B) ONL thickness measurement throughout the retina, every 500µm, showed protective effect 
of Tf only in the inferior pole. All values are represented as mean ±SEM; TfLE retinas were compared to BLE at 
each different distance from the optic nerve with one-way ANOVA, Bonferroni post-test; n=8 eyes per group; *** 
p<0.001. BLE: Rats injected with BSS and exposed to light (red line); NLE: Control rats neither injected nor 
exposed to light (black line); TfLE: Rats injected with human Tf and exposed to light (blue line). 
Figure 10: Non-viral gene therapy for local transferrin production preserves photoreceptors in 2 models of retinal 
degeneration.  
 (A) Histology of the retina following electrotransfer of empty plasmid (pVAX1) or containing cDNA of transferrin 
(pVAX1-Tf). (B) Mean ONL thickness evaluated on historesin semi-thin retinal sections in control rats (black bar), and 
12 days after ET of pVAX1 (red bar) or pVAX1-Tf (blue bar) in rats. ET and substained production of Tf had no 
deleterious effect on retina structure. (C) Historesin sections (D) and mean of ONL thickness of rats electrotransfered 
with pVAX1 (red bar) or pVAX-Tf (blue bar), submitted to light-exposure (LE) 3 days after, and sacrificed 8 days later. 
Control rats not ET but exposed to light are represented with black bar (control, LE). (E) Historesin sections and mean 
of ONL thickness (F) of P23H rats retinas (black bar), model of slow retinal degeneration, electrotransfered at 4 weeks 
of age with pVAX1 (red bar) or pVAX-Tf plasmids (blue bar), and sacrificed 4 weeks later. Scale bar: 100µm; All values 
are represented as mean ±SEM; One-way ANOVA, Bonferroni post-test; n=6-10 eyes per group; *p<0.05; *** 
p<0.001; ns=not significant.  
Figure 11: Treatments with transferrin remove retinal iron deposits in a mouse model of iron overload.  
(A) Iron staining (blue) by Perls method in the RPE of 32 weeks-old mice Bmp6-/- (control), intraperitoneally (IP) 
injected with BSS or Tf. Sections were counterstained with nuclear red. RPE: Retinal pigment epithelium. Scale bar: 
10µm. (B) Quantification of iron staining in retinal pigment epithelium (RPE) in 32 weeks-old Bmp6 KO mice (black 
bar), treated with Tf (blue bar) or BSS (red bar) by IP injections, 3 times per week for one month, or with a single 
intravitreal injection. All values are represented as mean ±SEM; Student’s t-test; n=4-6 retinas per group; *p=0.0475; 
**p=0.0035  
Supplementary Figure 1: Supplementary electroretinograms recording confirme partial preservation of retinal 
functions following transferrin injection.  
Mixed (rods+cones-driven responses) ERG were recorded 16 days after light-exposure. Negative a-waves represent 
photoreceptors responses and positive b-waves are relevant for post-receptoral responses. (A) As light-exposure 
induced a drastic collapse of the mixed a- and b-waves amplitudes, Tf injection significantly preserved nearly 50% of 
physiological responses of the retina. (B) Light exposure increased a- and b-waves implicit times (time of stimulus to 
peak time), and Tf injection normalized both values. All values are represented as mean ±SEM. One-way ANOVA, 
Bonferroni post-test; n=8 eyes per group; * p<0.05; ** p<0.01; *** p<0.001.; ns: not significant.  
BLE: Rats injected with BSS and exposed to light (red bars); NLE: Control rats neither injected nor exposed to light 
(black bars); TfLE: Rats injected with human Tf and exposed to light (blue bars). 
Supplementary Figure
Supplementary Figure 2: Analysis of transferrin produced after electrotransfer  
 (A) Western blot analysis of transferrin (Tf ) expression in ARPE-19 cell culture medium 3 days after 
transfection with control empty plasmid (pVAX1) or a plasmid containing human Tf cDNA (pVAX1-Tf). 
Positive control was done by culture cell medium added with Tf extracted from human plasma. (B) 
human Tf-ELISA assay was performed on vitreous and aqueous humor (ng/ml), and in neural retinas 
and eye cups (ng/tissue), 3 days after electrotransfer (ET) of pVAX1-Tf plasmid in rats. All values are 
represented as mean ±SEM; n=3-4 rats per group.   
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